"Ultimately, there is no 'right choice' when it comes to urinary diversion," writes Anne K. Schuckman, MD. Schuckman is an associate professor of urology/urologic oncology at the Keck School of ...

Piflufolastat F18 yields high detection rate even at low PSA levels for prostate cancer ...

“The main challenge at the moment is patients are being diagnosed with metastatic disease far earlier than they would have been otherwise, and therefore [are being] considered for combination systemic ...

The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands. Lutetium (177 Lu) rhPSMA-10.1 injection showed encouraging ...

Experts briefly mention other ongoing phase 3 studies investigating TAR-200 for the treatment of non–muscle-invasive bladder cancer (NMIBC).

The FDA authorized the EAP last month 2 to provide an alternative source of BCG to patients across the US in an effort to address the ongoing BCG shortage. “Constrained BCG supply has improved ...

Experts discuss the patient demographics and clinical trial design of the phase 2b SunRISe-1 study investigating the use of TAR-200 as a monotherapy and in combination with cetrelimab (a PD-1 ...

Panelists discuss how adapting the PEACE-3 protocol to real-world US patient populations requires careful consideration of broader patient demographics, comorbidities, and prior treatment histories ...

"The relaxation of the restrictions that started during COVID are critically important for continued access," says Mark T. Edney, MD. Many of the telehealth flexibilities that were implemented during ...

Panelists discuss how regulatory approval of the radium-223 and enzalutamide combination would likely lead to significant guideline updates, particularly in treatment sequencing recommendations for ...

“For someone that might be looking at getting into sacral neuromodulation, and has had some reluctance in the past, this does simplify the procedure somewhat," says Colin Goudelocke, MD. Six-month ...

An expert discusses how non–muscle invasive bladder cancer (NMIBC) treatment involves evolving delivery systems, transitioning from traditional systemic and intravesical approaches to advanced ...